Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Journal Article
·
· Nature Immunology
more »
- Walter Reed Army Institute of Research, Silver Spring, MD (United States); Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD (United States)
- Rockefeller Univ., New York, NY (United States)
- George Washington Univ., Washington, DC (United States)
- Walter Reed Army Institute of Research, Silver Spring, MD (United States)
- Integral Molecular, Philadelphia, PA (United States)
- National Institutes of Health (NIH), Bethesda, MD (United States). National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health (NIH), Bethesda, MD (United States). National Cancer Institute (NCI)
- Trudeau Institute, Saranac Lake, NY (United States)
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- National Cancer Institute; National Institutes of Health (NIH); USDOD; USDOE Office of Science (SC); Vaccine Research Center
- Grant/Contract Number:
- AC02-06CH11357
- OSTI ID:
- 1837258
- Alternate ID(s):
- OSTI ID: 1839744
OSTI ID: 1901205
- Journal Information:
- Nature Immunology, Journal Name: Nature Immunology Journal Issue: 12 Vol. 22; ISSN 1529-2908
- Publisher:
- Nature Research, Springer NatureCopyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
Journal Article
·
Sun Jul 02 20:00:00 EDT 2023
· Journal of Virology
·
OSTI ID:2423689